ENTEROME Bioscience has entered into a collaborative development agreement with AbbVie.
The alliance is anchored around Enterome's proprietary metagenomic biomarker portfolio and technologies that may enable the development of novel diagnostic products to support personalized therapies and the development of new drugs in microbiome-related diseases.
The companies will first collaborate to develop non-invasive monitoring tools of the gut microbiome in Crohn's disease.
In this complementary partnership, Enterome's expertise in the microbiome space and AbbVie's extensive development capabilities in the Inflammatory Bowel Disease (IBD) space present a clear opportunity to co-develop a customized solution enabling routine monitoring of Crohn's disease by evaluating disease activity in order to make improved treatment decisions.
For further deal information visit Current Agreements (subscription required)
Related
Report: Top 50 Big Pharma Partnering and M&A Deal Trends
Report: Top 50 Big Biotech Partnering and M&A Deal Trends
